Pharmaceuticals, Biotechnology and Life Sciences
BioPharmX posted net loss for the second quarter ended July 31, 2019 was $2.6 million, or $0.22 per share, compared with a net loss of $4.4 million, or $0.58 per share, during the prior fiscal year’s second quarter.
MINNEAPOLIS–(BUSINESS WIRE)–Celcuity Inc. (Nasdaq: CELC), a functional cellular analysis company that is discovering new cancer subtypes and developing diagnostic tests…
FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2…
Leading customer engagement software firm adds new CFO Phil Hoey and VP North American Sales Dave Butler to growing team…
LONDON–(BUSINESS WIRE)–#Biotechnology–The global Tourette’s syndrome drugs market size is poised to reach USD 98.77 million by 2023, according to a…
RONKONKOMA, N.Y.–(BUSINESS WIRE)–#advisoryboard–Qosina is pleased to announce that Scott Herskovitz, President and CEO, has joined the Medical Advisory Board (MAB)…
September is time to spread knowledge, show support and help fund those affected by pulmonary fibrosis BERWYN, Pa.–(BUSINESS WIRE)–In recognition…
LONDON–(BUSINESS WIRE)–#Healthcare–The global gene amplification technologies market size is poised to reach USD 300.28 million by 2023, according to a…
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier…
Global clinical programme is the first to study this severely ill patient population, who are typically excluded from antidepressant treatment…